Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Vaccines

  Free Subscription


16.06.2025

1 BMJ
1 Clin Microbiol Rev
1 J Infect Dis
1 J Pediatr
2 J Virol
2 JAMA
1 Lancet
1 Nat Med
2 Pediatr Infect Dis J
1 PLoS Comput Biol
7 PLoS One
25 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMJ

  1. TAYLOR L
    RFK Jr dismisses entire CDC vaccine advisory panel.
    BMJ. 2025;389:r1206.
    PubMed        


    Clin Microbiol Rev

  2. JIAN N, Yu L, Ma L, Zheng B, et al
    BCG therapy in bladder cancer and its tumor microenvironment interactions.
    Clin Microbiol Rev. 2025 Mar 20:e0021224. doi: 10.1128/cmr.00212.
    PubMed         Abstract available


    J Infect Dis

  3. SONG Y, Deng B, Long CA, Li Q, et al
    Priming or Boosting P. falciparum Transmission Blocking Responses with Recombinant Vaccines or Gametocyte Extract.
    J Infect Dis. 2025 Jun 12:jiaf318. doi: 10.1093.
    PubMed         Abstract available


    J Pediatr

  4. TAM J, Modler J, Bettinger JA, Burton C, et al
    Influenza-Associated Mortality Among Children in Canada from 2004 to 2022.
    J Pediatr. 2025;282:114594.
    PubMed         Abstract available


    J Virol

  5. LIU M, Aryal B, Niu X, Wang Q, et al
    Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.
    J Virol. 2025 Jun 12:e0045125. doi: 10.1128/jvi.00451.
    PubMed         Abstract available

  6. SCHLEISS MR, Fernandez-Alarcon C, Bierle CJ, Geballe AP, et al
    Replication-deficient whole-virus vaccines against cytomegalovirus induce protective immunity in a guinea pig congenital infection model.
    J Virol. 2025 Jun 11:e0020725. doi: 10.1128/jvi.00207.
    PubMed         Abstract available


    JAMA

  7. GOSTIN LO, Reiss D, Offit PA
    Changed Recommendations for COVID-19 Vaccines for Children and Pregnant Women: A Failure of Process, Policy, and Science.
    JAMA. 2025 Jun 13. doi: 10.1001/jama.2025.10658.
    PubMed        

  8. ZETTLER PJ, Cha S, Despres S, Lurie P, et al
    FDA Review of Novavax's COVID-19 Vaccine-Regulatory Integrity and Deviations From Standard Practice.
    JAMA. 2025 Jun 9. doi: 10.1001/jama.2025.9898.
    PubMed        


    Lancet

  9. LARSON H
    Vaccination: a changing political, scientific, and personal landscape.
    Lancet. 2025 Jun 5:S0140-6736(25)01193-6. doi: 10.1016/S0140-6736(25)01193.
    PubMed        


    Nat Med

  10. RIBEIRO DOS SANTOS G, Jawed F, Mukandavire C, Deol A, et al
    Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.
    Nat Med. 2025 Jun 10. doi: 10.1038/s41591-025-03703.
    PubMed         Abstract available


    Pediatr Infect Dis J

  11. TACHIKAWA J, Aizawa Y, Ikuse T, Yamanaka T, et al
    Clinical Characteristics of Hospitalized Children With Coronavirus Disease 2019 After the Spread of the BA.5 Omicron Variants in Japan.
    Pediatr Infect Dis J. 2025;44:665-671.
    PubMed         Abstract available

  12. CAVALCANTE LRL, Los DB, Fiorenza NG, Kehdi RC, et al
    Maternal Immunization Against SARS-CoV-2 and Infant Immunity Persistence in a Brazilian Cohort.
    Pediatr Infect Dis J. 2025 Apr 9. doi: 10.1097/INF.0000000000004817.
    PubMed         Abstract available


    PLoS Comput Biol

  13. VOUTOURI C, Munn LL, Stylianopoulos T, Jain RK, et al
    Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions.
    PLoS Comput Biol. 2025;21:e1013163.
    PubMed         Abstract available


    PLoS One

  14. BURHAN E, Azzumar F, Sinuraya FAG, Prasetyo S, et al
    Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and Omicron wave in Jakarta, Indonesia: A test-negative case-control study.
    PLoS One. 2025;20:e0320779.
    PubMed         Abstract available

  15. LOGANATHAN T, Zaini AZ, Majid HA
    Exploring the barriers and facilities migrants face in accessing COVID-19 vaccines in Malaysia: A qualitative study.
    PLoS One. 2025;20:e0326045.
    PubMed         Abstract available

  16. KUATEWO M, Ebelin W, Doegah PT, Aberese-Ako M, et al
    Fake news, misinformation, vaccine hesitancy and the role of community engagement in COVID-19 vaccine acceptance in Southern Ghana.
    PLoS One. 2025;20:e0316969.
    PubMed         Abstract available

  17. ENYEW EB, Kasaye MD, Kebede SD, Feyisa MS, et al
    Human Papillomavirus Vaccination uptake and associated factors among schools girls aged between 9-14 years in Ethiopia: Performance Monitoring for Action (PMA-ET) 2023, multilevel analysis.
    PLoS One. 2025;20:e0325557.
    PubMed         Abstract available

  18. ATAC O, Peterson LE, Waters TM
    The impact of the COVID-19 pandemic on vaccinations in United States primary care practices.
    PLoS One. 2025;20:e0325934.
    PubMed         Abstract available

  19. LI L, Back SI, Ma J, Guo Y, et al
    Bayesian optimization and machine learning for vaccine formulation development.
    PLoS One. 2025;20:e0324205.
    PubMed         Abstract available

  20. CAHN P, Barreto L, Figueroa MI, Fink V, et al
    Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH).
    PLoS One. 2025;20:e0312893.
    PubMed         Abstract available


    Vaccine

  21. LUYTEN J, van Hoek AJ
    Reasons for excluding adverse events in cost-effectiveness analyses of vaccines: A survey amongst authors.
    Vaccine. 2025;61:127341.
    PubMed         Abstract available

  22. JORDAN Z, Roderick M, Marlow R, Rowland E, et al
    "I'm not aware of anyone having died from chickenpox?": Acceptability of varicella vaccination in the UK, a mixed methods questionnaire and interview study.
    Vaccine. 2025;61:127322.
    PubMed         Abstract available

  23. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
    Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
    Vaccine. 2025;61:127376.
    PubMed         Abstract available

  24. FAWOLE A, Boyer B, Shahid M, Bharali I, et al
    What are the key features of an equitable global vaccine strategy for the next pandemic? A qualitative study of pandemic control experts.
    Vaccine. 2025;61:127377.
    PubMed         Abstract available

  25. QIN XX, Deng M, Wu J, Yang J, et al
    Cellular response, persistent humoral response and efficacy elicited by a CV-A16 vaccine candidate in mice.
    Vaccine. 2025;61:127276.
    PubMed         Abstract available

  26. OMAR M, Shibli H, Edelstein M
    Comparative impact of the COVID-19 pandemic on parental behaviour towards childhood vaccination in Israel and the United Kingdom: A self-controlled matched cross-sectional study.
    Vaccine. 2025;61:127385.
    PubMed         Abstract available

  27. KEUTLER A, Lainka E, Hudert C, Bufler P, et al
    Erratum to "Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study" [Vaccine 59 (2025) 127288].
    Vaccine. 2025;61:127357.
    PubMed        

  28. BERGER MN, Davies C, Mathieu E, Harmer-Ross J, et al
    Perceived safety, usability, and acceptability of microarray patches for vaccination among key populations: A mixed methods study.
    Vaccine. 2025;61:127387.
    PubMed         Abstract available

  29. MOK CC, Chan KL, Tse SM
    Long-term immunogenicity of a live attenuated herpes zoster vaccine in patients with systemic lupus erythematosus.
    Vaccine. 2025;61:127365.
    PubMed         Abstract available

  30. LIU X, Li J, Zha Y, Wang Z, et al
    The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, doub
    Vaccine. 2025;61:127289.
    PubMed         Abstract available

  31. MARIN-CABA E, Benavente-Fernandez A, Morales-Jimenez G, Comino-Fernandez S, et al
    Evaluation of vaccine uptake and opportunity of in-hospital vaccination against pneumococcus in vulnerable hospitalized patients.
    Vaccine. 2025;61:127364.
    PubMed         Abstract available

  32. WILLIS DE, Moore R, Selig JP, Amin NS, et al
    Corrigendum to "Pediatric HPV vaccination: Provider recommendations matter among hesitant parents" [Vaccine 42(25) (2025) 126166].
    Vaccine. 2025;61:127343.
    PubMed        

  33. MOSHIRIAN FARAHI SMM, Xu Y, Dort J, Caulley L, et al
    Factors associated with COVID-19 vaccine confidence among Arab, Asian, Black, Indigenous, and White individuals in Canada: Latent profile analyses.
    Vaccine. 2025;61:127358.
    PubMed         Abstract available

  34. ARCOLACI A, Guidolin L, Olivieri E, Bilo MB, et al
    A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines.
    Vaccine. 2025;61:127337.
    PubMed         Abstract available

  35. DUSSAULT JM, Rivera Torres AF, Oudin Doglioni D, Gagneux-Brunon A, et al
    The effect of school-based interventions on HPV vaccine-related knowledge, attitudes, and practices among adolescents in France: Secondary results from the PrevHPV trial.
    Vaccine. 2025;61:127344.
    PubMed         Abstract available

  36. KIM SH, You SH, Lee JW, Kim E, et al
    Association between COVID-19 vaccination and first healthcare utilization for chronic obstructive pulmonary disease: A nationwide population-based cohort study.
    Vaccine. 2025;61:127367.
    PubMed         Abstract available

  37. TSCHERNE A, Krammer F
    A review of currently licensed mucosal COVID-19 vaccines.
    Vaccine. 2025;61:127356.
    PubMed         Abstract available

  38. ROSENMAN KD, Wang L
    Variation of COVID-19 vaccination percentage by industry and occupation in Michigan.
    Vaccine. 2025;61:127349.
    PubMed         Abstract available

  39. GARFIELD S, Ali F, Murdan S
    Enhancing faith and interfaith based facilitators and reducing related barriers to enhance vaccine acceptance: a qualitative study.
    Vaccine. 2025;61:127348.
    PubMed         Abstract available

  40. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Psychometric validation of the COVID-19 vaccine hesitancy scale for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;61:127368.
    PubMed         Abstract available

  41. LAPEYRE R, Rezk N, McClean S, Moore AC, et al
    Systematic mapping review of preclinical and clinical studies of Staphylococcus aureus vaccines.
    Vaccine. 2025;61:127333.
    PubMed         Abstract available

  42. SIEVERS BL, Sievers EL
    It's time to change how we vaccinate for measles.
    Vaccine. 2025;61:127382.
    PubMed         Abstract available

  43. MARTINS RM, Maia MLS, Camacho LAB, Noronha TG, et al
    Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children.
    Vaccine. 2025;61:127363.
    PubMed         Abstract available

  44. DONG X, Schillie SF, McNamara LA, Leidner AJ, et al
    Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the United States.
    Vaccine. 2025;61:127332.
    PubMed         Abstract available

  45. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 17-21 February 2025.
    Vaccine. 2025;61:127384.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.